Advertisement

Kombination von Zytostatika mit Strahlentherapie: Radiochemotherapie

  • D. Gencer
Chapter

Zusammenfassung

Chemo- und Strahlentherapie können simultan und sequenziell erfolgen.

Literatur

  1. Amado RG, Wolf M, Peeters M et al. (2008) Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26(10):1626-34. Epub 2008 Mar 3. PubMed PMID: 18316791PubMedCrossRefGoogle Scholar
  2. Ang KK, Zhang QE, Rosenthal DI et al. (2011) A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III–IV head and neck squamous cell carcinomas. J Clin Oncol; 29 (suppl; abstr. 5500)Google Scholar
  3. Antonadou D, Paraskevaidis M, Sarris G et al. (2002) Phase II randomized trial of temozolomide and concurrent radiotherapy in patients with brain metastases. J Clin Oncol 20:3644–3650PubMedCrossRefGoogle Scholar
  4. Aschele C, Pinto C, Cordio S et al. (2009) Preoperative fluorouracil (FU)-based chemoradiation with and without weekly oxaliplatin in locally advanced rectal cancer: Pathologic response analysis of the Studio Terapia Adiuvante Retto (STAR)-01 randomized phase III trial. J Clin Oncol 18S:804S; CRA4008Google Scholar
  5. Bengala C, Bettelli S, Bertolini F et al. (2009) Epidermal growth factor receptor gene copy number, K-ras mutation and pathological response to preoperative cetuximab, 5-FU and radiation therapy in locally advanced rectal cancer. Ann Oncol 20(3):469–474PubMedCrossRefGoogle Scholar
  6. Berardi R, Porfiri E, Scartozzi M et al. (2003) Elderly patients with advanced non-small cell lung cancer. A phase II study with weekly cisplatin and gemcitabine. Oncology 65(3): 198–203PubMedCrossRefGoogle Scholar
  7. Blackstock AW, Hess S, Chaney S et al. (1999) Oxaliplatin: in vitro evidence of its radiation sensitizing activity. Preclinical observations relevant to clinical trials. Int J Radiat Oncol Biol Phys 45:253CrossRefGoogle Scholar
  8. Blaszkowsky LS, Hong TS, Zhu AX, et al. (2009). A phase I/II study of bevacizumab (beva), erlotinib (erl), and 5-fluorouracil (5-FU) with concurrent external beam radiation therapy (RT) in locally advanced rectal cancer. J Clin Oncol 27:15s (suppl; abstr 4106).Google Scholar
  9. Bonner JA, Harari PM, Giralt J, Cohen, et al. (2010). Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer. 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 11:21–28PubMedCrossRefGoogle Scholar
  10. Budach W, Paulsen F, Welz S et al. (2002) Mitomycin C in combination with radiotherapy as a potent inhibitor of tumour cell repopulation in a human squamous cell carcinoma. Br J Cancer 86:470–476PubMedCrossRefGoogle Scholar
  11. Caponigro F, Romano C, Milano A et al. (2008) A phase I/II trial of gefitinib and radiotherapy in patients with locally advanced inoperable squamous cell carcinoma of the head and neck. Anticancer Drugs 19(7):739–744PubMedCrossRefGoogle Scholar
  12. Cappuzzo F, Ciuleanu T, Stelmakh L et al. (2009) SATURN: A double-blind, randomized, phase III study of maintenance erlotinib versus placebo following nonprogression with first-line platinum-based chemotherapy in patients with advanced NSCLC. J Clin Oncol 27:7s, (Suppl); abstr 8001Google Scholar
  13. Carraro S, Roca EL, Cartelli C et al. (2002) Radiochemotherapy with short daily infusion of low-dose oxaliplatin, leucovorin, and 5-FU in T3-T4 unresectable rectal cancer: a phase II IATTGI study. Int J Radiat Oncol Biol Phys 54:397–402PubMedCrossRefGoogle Scholar
  14. Choy H, Kim DW (2003) Chemotherapy and irradiation interaction. Sem Oncol 30(Suppl 9):3–10CrossRefGoogle Scholar
  15. Cividalli A, Ceciarelli F, Livdi E et al. (2002) Radiosensitization by oxaliplatin in a mouse adenocarcinoma: influence of treatment schedule. Int J Radiat Oncol Biol Phys 52:1092–1098PubMedCrossRefGoogle Scholar
  16. Crane C, Crane CH, Eng C et al. (2010) Phase II trial of neoadjuvant bevacizumab, capecitabine, and radiotherapy for locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 76(3):824–830PubMedCrossRefGoogle Scholar
  17. Czito BG, Bendell JC, Willett CG et al. (2007) Bevacizumab, oxaliplatin, and capecitabine with radiation therapy in rectal cancer: Phase I trial results. Int J Radiat Oncol Biol Phys 68(2):472–478PubMedCrossRefGoogle Scholar
  18. Davies Cde L, Lundstrom LM, Frengen J et al. (2004) Radiation improves distribution and uptake of liposomal doxorubicin (caelyx) in human osteosarcoma xenografts. Cancer Res 64:547–553PubMedCrossRefGoogle Scholar
  19. Debucquoy A, Haustermans K, Daemen A et al. (2009). Molecular response to cetuximab and efficacy of preoperative cetuximab-based chemoradiation in rectal cancer. J Clin Oncol 27(17):2751–2757PubMedCrossRefGoogle Scholar
  20. Di Petrillo T, Pricolo V, Lagares-Garcia J et al. (2009) Neoadjuvant bevacizumab, oxaliplatin, 5-fluorouracil, and radiation in clinical stage II-III rectal cancer J Clin Oncol 27:15s (suppl; abstr 4105)Google Scholar
  21. Douillard JY, Cunningham D, Roth AD et al. (2000) Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicenter randomised trial. Lancet 355:1041–1047PubMedCrossRefGoogle Scholar
  22. Dunst J, Reese T, Setter T et al. (2002) Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer. J Clin Oncol 20:3983–3991PubMedCrossRefGoogle Scholar
  23. De Lange SM, van Groeningen CJ, Mejer OWM et al. (2002) Gemcitabine-radiotherapy in patients with locally advanced pancreatic cancer. Eur J Cancer 38:1212–1217PubMedCrossRefGoogle Scholar
  24. Epelbaum R, Rosenblatt E, Nasrallah S et al. (2002) Phase II study of gemcitabine combined with radiation therapy in patients with localized, unresectable pancreatic cancer. J Surg Oncol 81:138–143PubMedCrossRefGoogle Scholar
  25. Erben P, Ströbel P, Horisberger K et al. (2010) KRAS & BRAF mutations and PTEN expression do not predict efficacy of cetuximab-based chemoradiotherapy in locally advanced rectal cancer. Int J Radiat Oncol Biol Phys [im Review]Google Scholar
  26. Feliu J, Calvillo J, Escribano A et al. (2002) Neoadjuvant therapy of rectal carcinoma with UFT-leucovorin plus radiotherapy. Ann Oncol 13:730–736PubMedCrossRefGoogle Scholar
  27. Flam MS, John M, Pajak T et al. (1996) Role of mitomycin C in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study. J Clin Oncol 14:2527–2539PubMedGoogle Scholar
  28. Freyer G, Bossard N, Romestaing P et al. (2001) Addition of oxaliplatin to continuous fluorouracil, L-folinic acid, and concomitant radiotherapy in rectal cancer: the Lyon R97–03 phase I trial. J Clin Oncol 19:2433–2438PubMedGoogle Scholar
  29. Gerard JP, Chalet O, Nemoz C et al. (2003) Preoperative concurrent chemoradiotherapy in locally advanced rectal cancer with high-dose radiation and oxaliplatin-containing regimen: the Lyon R0–04 phase II trial. J Clin Oncol 21:1119–1124PubMedCrossRefGoogle Scholar
  30. Gerard JP, Azria D, Gourgou-Bourgade S, et al. Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige 2. J Clin Oncol 28:1638–1644Google Scholar
  31. Giaccone G, Herbst RS, Manegold C et al. (2004) Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial – INTACT 1. J Clin Oncol 22:777–784PubMedCrossRefGoogle Scholar
  32. Glimelius B, Jakobsen A, Graf W et al. (1998) Bolus injection (2–4 min) versus short-term (10–20 min) infusion of 5-fluorouracil in patients with advanced colorectal cancer: a prospective randomised trial. Nordic Gastrointestinal Tumour Adjuvant Therapy Group. Eur J Cancer 34:674–678PubMedCrossRefGoogle Scholar
  33. Glynne-Jones R, Sebag-Montefiore D, McDonald A et al. (2003) Phase I/II study of preoperative radiation and capecitabine in combination with oxaliplatin in locally advanced rectal cancer: the Socrates study. Proc Am Soc Clin Oncol 22:1174Google Scholar
  34. Glynne-Jones R, Meadows H, Wan S et al. (2008) EXTRA--a multicenter phase II study of chemoradiation using a 5 day per week oral regimen of capecitabine and intravenous mitomycin C in anal cancer. National Cancer Research Institute Anal Sub Group and Colorectal Clinical Oncology Group. Int J Radiat Oncol Biol Phys 72(1):119–126PubMedCrossRefGoogle Scholar
  35. Glynne-Jones R, Mawdsley S, Harrison M et al. (2010) Cetuximab and chemoradiation for rectal cancer – is the water getting muddy? Acta Oncol [Epub ahead of print]Google Scholar
  36. Hainsworth JD, Spigel DR, Burris HA 3rd et al (2009) Neoadjuvant chemotherapy/gefitinib followed by concurrent chemotherapy/radiation therapy/gefitinib for patients with locally advanced squamous carcinoma of the head and neck. Cancer 115(10):2138–46PubMedCrossRefGoogle Scholar
  37. Hartmann JT, Oechsle K, Quietzsch D et al. (2003) Protracted infusional 5-fluorouracil plus high-dose folinic acid combined with bolus mitomycin C in patients with gastrointestinal cancer: a phase I/II dose escalation study. Br J Cancer 89:2051–2056PubMedCrossRefGoogle Scholar
  38. Hassel JC, Kripp M, Al-Batran S, Hofheinz RD. Treatment of epidermal growth factor receptor antagonist-induced skin rash: results of a survey among German oncologists. Onkologie 33(3):94-8. Epub 2010 Feb 22. PubMed PMID: 20215799Google Scholar
  39. Hegi ME, Diserens AC, Gorlia T et al. MGMT silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352: 997–1003Google Scholar
  40. Heidelberger C, Chaudhuari NK, Danneberg P et al. (1957) Fluorinated pyrimidines: a new class of tumor inhibitory compounds. Nature 179:2557–2560CrossRefGoogle Scholar
  41. Heidelberger C, Griesbach L, Montag BJ et al. (1958) Studies on fluorinated pyrimidines II. Effects of transplanted tumors. Cancer Res 18:305–317PubMedGoogle Scholar
  42. Herbst RS, O’Reilly MS (2003) The rationale and potential of combining novel biologic therapies with radiotherapy: focus on non-small cell lung cancer. Sem Oncol 30(Suppl 9): 113–123CrossRefGoogle Scholar
  43. Herbst RS, Giaccone G, Schiller JH et al. (2004) Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial – INTACT 2. J Clin Oncol 22:785–794PubMedCrossRefGoogle Scholar
  44. Hirose Y, Berger, Pieper RO (2001) P53 effects both the duration of G2/M arrest and the fate of temozolomide-treated human glioblastoma cells. Cancer Res 61:1957–1963PubMedGoogle Scholar
  45. Hoff PM, Janjan N, Saad ED et al. (2000) Phase I study of preoperative oral uracil and tegafur plus leucovorin and radiation therapy in rectal cancer. J Clin Oncol 18:3529–3534PubMedGoogle Scholar
  46. Hofheinz R, Hartmann J, Hartung G et al. (2003) Increasing doses of capecitabine in combination with mitomycin: a phase I study in patients with pretreated gastrointestinal cancer. Proc Am Soc Clin Oncol 22:1316Google Scholar
  47. Hofheinz R, von Gerstenberg-Helldorf B, Wenz F et al. (2004) Phase-I-study of irinotecan (CPT-11) and capecitabine in combination with concurrent radiotherapy for locally advanced rectal cancer. Proc Am Soc Clin Oncol 23:2203Google Scholar
  48. Jensen JN, Lock-Andersen J, Langer SW et al. (2003) Dexrazoxane – a promising antidote in the treatment of accidental extravasation of anthracyclines. Scand J Plast Reconstr Hand Surg 37:174–175CrossRefGoogle Scholar
  49. Khushalani NI, Leichman CG, Proulx G et al. (2002) Oxaliplatin in combination with protracted-infusion fluorouracil and radiation: report of a clinical trial for patients with esophageal cancer. J Clin Oncol 20:2844–2850PubMedCrossRefGoogle Scholar
  50. Klautke G, Kirchner R, Hopt U et al. (2001) Continuous infusion of 5-FU and weekly irinotecan with concurrent radiotherapy as neoadjuvant treatment for locally advanced or recurrent rectal cancer. Proc Am Soc Clin Oncol 20:555Google Scholar
  51. Kretzschmar A, Pink D, Thuss-Patience P et al. (2003) Extravasations of oxaliplatin. J Clin Oncol 21:4068–4069PubMedCrossRefGoogle Scholar
  52. Kris MG, Natale RB, Herbst RS et al. (2003) Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small-cell lung cancer. A randomized trial. JAMA 290:2149–2158PubMedCrossRefGoogle Scholar
  53. Kuten A, Anacak Y, Abdah-Bortnyak R et al. (2003) Neoadjuvant radiotherapy concurrent with weekly paclitaxel and carboplatin and followed by surgery in locally advanced non-small-cell lung cancer. Am J Clin Oncol 26:184–187PubMedCrossRefGoogle Scholar
  54. Lanzetta G, Campanella C, Rozzi A et al. (2003) Temozolomide in radio-chemotherapy combination treatment for newly diagnosed glioblastoma multiforme: phase II clinical trial. Anticancer Res 23:5159–5164PubMedGoogle Scholar
  55. Li G, Hu W, Wang J et al. (2010) Phase II Study of Concurrent Chemoradiation in Combination with Erlotinib for Locally Advanced Esophageal Carcinoma. Int J Radiat Oncol Biol Phys [Epub ahead of print] PubMed PMID: 20350790Google Scholar
  56. Lövey J, Koronczay K, Remenár E et al. (2003) Radiotherapy and concurrent low-dose paclitaxel in locally advanced head and neck cancer. Radiother Oncol 68:171–174PubMedCrossRefGoogle Scholar
  57. Loibl S, von Minckwitz G, Schwedler K et al. (2003) Mitomycin, folinic acid, 5-FU (Mi-Fo-FU) as salvage chemotherapy for hepatic failure due to liver metastases in breast cancer. Proc Am Soc Clin Oncol 22:326Google Scholar
  58. Mader I, Fürst-Weger PR, Mader RM (Hrsg) (2002) Paravasation von Zytostatika. Ein Kompendium für Prävention und Therapie. Springer, Berlin Heidelberg New York TokioGoogle Scholar
  59. Marijnen CA (2008) Preoperative chemoradiotherapy regimen with capecitabine and bevacizumab in locally advanced rectal cancer: a feasibility study of the Dutch Coloretcal Cancer Group (DCCG). J Clin Oncol 26: (suppl; abstr 15040)Google Scholar
  60. Marquardt F, Rödel F, Capalbo G et al. (2009) Molecular targeted treatment and radiation therapy for rectal cancer. Strahlenther Onkol 185(6):371–378PubMedCrossRefGoogle Scholar
  61. Mason KA, Hunter NR, Milas M et al. (1997) Docetaxel enhances tumor radioresponse in vivo. Clin Cancer Res 3:2431–2438PubMedGoogle Scholar
  62. Maurer AM, Masters GA, Haraf DJ et al. (1998) Phase I study of docetaxel with concomitant thoracic radiation therapy. J Clin Oncol 16:159–164Google Scholar
  63. Mehta VK, Cho CC, Ford JM et al. (2003) Phase II trial of preoperative 3D conformal radiotherapy, protracted venous infusion 5-fluorouracil, and weekly CPT-11, followed by surgery for ultrasound-staged T3 rectal cancer. Int J Radiat Oncol Biol Phys 55:132–137PubMedCrossRefGoogle Scholar
  64. Meyer JL, Vaeth JM (Hrsg) (1992) Radiotherapy/chemotherapy interactions in cancer treatment. KargerGoogle Scholar
  65. Molls M (1996) Prinzipien der Kombination von Radiotherapie und Chemotherapie. In: Scherer E, Sack H (Hrsg) Strahlentherapie. Radiologische Onkologie. Springer, Berlin Heidelberg New York Tokio, S 189–205Google Scholar
  66. Moore MJ, Goldstein D, Hamm J et al. (2007) Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25(15):1960–1966PubMedCrossRefGoogle Scholar
  67. Mose S, Class R, Weber HW et al. (2002) Kombination von Radiotherapie und Gemcitabine. Bewertung klinischer Daten auf der Basis experimenteller Erkenntnisse. Strahlenther Onkol 178:59–70PubMedCrossRefGoogle Scholar
  68. Mudad R, Ramsey M, Kovitz K et al. (2003) Concomitant weekly docetaxel, cisplatin and radiation therapy in locally advanced non-small cell lung cancer: a dose finding study. Lung Cancer 39:173–177PubMedCrossRefGoogle Scholar
  69. Nogue M, Salud A, Vicente P et al. (2009) Addition of bevacizumab to induction plus concomitant capecitabine-oxaliplatin (XELOX) chemoradiotherapy (CRT) in MRI poor prognosis locally advanced rectal cancer: Avacross study. J Clin Oncol 18S:193S; 4100Google Scholar
  70. O’Connell MJ, Martenson JA, Weiand HS et al. (1994) Improving adjuvant therapy for rectal cancer by combining protracted infusion fluorouracil with radiation therapy after curative surgery. N Engl J Med 331:502–50PubMedCrossRefGoogle Scholar
  71. Resch G, de Vries A, Öfner D et al. (2010) Preoperative treatment with capecitabine (C), bevacizumab (B), and radiotherapy (RT) for primary locally advanced rectal cancer (LARC): A two-stage phase II clinical trial. ASCO GI Cancer Symposium 2010; Abstract No. 496.Google Scholar
  72. Rich TA, Kirichenko AV (2001) Camptothecin schedule and timing of administration with irradiation. Oncology 15 (Suppl 5):37–41PubMedGoogle Scholar
  73. Robert F, Ezekiel MP, Spencer SA et al. (2001) Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. J Clin Oncol 19:3234–3243PubMedGoogle Scholar
  74. Rödel C, Grabenbauer GG, Papadopoulos T et al. (2003) Phase I/II trial of capecitabine, oxaliplatin, and radiation for rectal cancer. J Clin Oncol 21:3098–3104PubMedCrossRefGoogle Scholar
  75. Rotman M, Aziz H, Wasserman TH (1997) Chemotherapy and irradiation. In: Perez CA, Brady LW et al. (eds) Principles and Practice of Radiation Oncology. Lippincott-Raven Publishers, S 705–722Google Scholar
  76. Saußele S, Petzold A, Gemünden C et al. (2003) DPD deficiency in patients treated with 5-fluorouracil and capecitabine detected by melting curve analysis. Onkologie 26 (Suppl 5):793Google Scholar
  77. Scagliotti GV, Manegold C, Buchholz E et al. (2002) Randomized phase II study evaluating the feasibility of thoracic radiotherapy with or without weekly docetaxel (taxotere) following induction chemotherapy with cisplatin and docetaxel in unresectable stage IIIA-B non-small cell lung cancer. Proc Am Soc Clin Oncol 21:1279Google Scholar
  78. Shepherd, FA, Pereira, J, Ciuleanu, TE, et al. (2005) Erlotinib in previously tested non-small cell lung cancer. N Engl J Med 353,123–132Google Scholar
  79. Schilsky RL (1992) Biochemical pharmacology of chemotherapeutic drugs used as radiation enhancers. Sem Oncol 19 (Suppl 11):2–7Google Scholar
  80. Spigel DR, Greco FA, Meluch AA et al. (2010) Phase I/II Trial of Preoperative Oxaliplatin, Docetaxel, and Capecitabine With Concurrent Radiation Therapy in Localized Carcinoma of the Esophagus or Gastroesophageal Junction. J Clin Oncol 28(13):2213–2219.Epub 2010 Mar 29.Google Scholar
  81. Steren A, Sevin BU, Perras J et al. (1993) Taxol sensitizes human ovarian cancer cells to radiation. Gyn Oncol 48: 282–285Google Scholar
  82. Stupp R, Mason WP, van den Bent et al. (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.N Engl J Med 352:987–996PubMedCrossRefGoogle Scholar
  83. Tempero M, Plunkett W, Ruiz Van Haperen V et al. (2003) Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol 21:3402–3408PubMedCrossRefGoogle Scholar
  84. Tepper JE, O’Connell MJ, Petroni GR et al. (1997) Adjuvant postoperative fluorouracil-modulated chemotherapy combined with pelvic radiation therapy for rectal cancer: initial results of intergroup 0114. J Clin Oncol 15:2030–2039PubMedGoogle Scholar
  85. Tishler RB, Geard CR, Hall EJ et al. (1992) Taxol sensitizes astrocytoma cells to radiation. Cancer Res 52:3495–3497PubMedGoogle Scholar
  86. Tony S. Mok, M.D., Yi-Long Wu, M.D. et al. (2009) Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma. N Engl J Med 361:2485–2487CrossRefGoogle Scholar
  87. Ulutin HC, Pak Y (2003) Preliminary results of radiotherapy with or without weekly paclitaxel in locally advanced nonsmall cell lung cancer. J Cancer Res Clin Oncol 129:52–56Google Scholar
  88. van Rijn J, Heimans JJ, van den Berg J et al. (2000) Survival of human glioma cells treated with various combinations of temozolomide and x-rays. Int J Radiat Oncol Biol Phys 47:779–784PubMedCrossRefGoogle Scholar
  89. Velenik V, Ocvirk J, Oblak I et al. (2010) A phase II study of cetuximab, capecitabine and radiotherapy in neoadjuvant treatment of patients with locally advanced resectable rectal cancer. Eur J Surg Oncol 36(3):244–250PubMedCrossRefGoogle Scholar
  90. Vestermark LW, Jacobsen A, Qvortrup C et al.(2008) Long-term results of a phase II trial of high-dose radiotherapy (60 Gy) and UFT/l-leucovorin in patients with non-resectable locally advanced rectal cancer (LARC). Acta Oncol 47(3):428–433PubMedCrossRefGoogle Scholar
  91. Wilkowski R, Thoma M, Heinemann V et al. (2003) Radiochemotherapie mit Gemcitabin und Cisplatin bei Pankreaskarzinom – durchführbar und effektiv. Strahlenther Onkol 179:78–86PubMedCrossRefGoogle Scholar
  92. Wilkowski R, Boeck S, Ostermaier S et al. (2009) Chemoradiotherapy with concurrent gemcitabine and cisplatin with or without sequential chemotherapy with gemcitabine/cisplatin vs chemoradiotherapy with concurrent 5-fluorouracil in patients with locally advanced pancreatic cancer--a multi-centre randomised phase II study. Br J Cancer 101(11):1853–1859PubMedCrossRefGoogle Scholar
  93. Willett CG, Boucher Y, di Tomaso E et al. (2004) Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 10(2):145–147PubMedCrossRefGoogle Scholar
  94. Willett CG, Duda DG, di Tomaso E et al. (2009) Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study.J Clin Oncol 27(18):3020–3026PubMedCrossRefGoogle Scholar
  95. Williams KJ, Telfer BA, Stratford IJ et al. (2001) Combination of ZD1839 (Iressa), an EGFR tyrosine kinase inhibitor, and radiotherapy increases antitumour efficacy in a human colon cancer xenograft model. Proc Am Ass Cancer Res 42:3840Google Scholar
  96. Workman P (1992) Infusional anthracyclines: is slower better? If so, why? Ann Oncol 3:591PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  • D. Gencer
    • 1
  1. 1.Interdisziplinäres Tumorzentrum Mannheim (ITM)TagesTherapieZentrum (TTZ)MannheimDeutschland

Personalised recommendations